[1] European Association for The Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol, 2018, 69: 406-460.
[2] Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 2021, 74: 1014-1048.
[3] 中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南.临床肝胆病杂志2017,33:1847-1863.
[4] Yoshiji H, Nagoshi S, Akahane T, et al. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol, 2021, 56: 593-619.
[5] Uojima H, Hidaka H, Tanaka Y, et al. Furosemide Dose Changes Associated with Furosemide/Tolvaptan Combination Therapy in Patients with Cirrhosis. Dig Dis, 2020, 38: 38-45.
[6] Bellos I, Kontzoglou K, Psyrri A, et al. Tolvaptan Response Improves Overall Survival in Patients with Refractory Ascites: A Meta-Analysis. Dig Dis, 2020, 38: 320-328.
[7] Hiramine Y, Uto H, Mawatari S, et al. Effect of tolvaptan on the prognosis of patients with hepatic ascites. Hepatol Res, 2019, 49: 765-777.
[8] Wang YF, Tang JT, Han T, et al. Tolvaptan in Chinese cirrhotic patients with ascites: A randomized, placebo-controlled phase 2 trial. J Dig Dis, 2018, 19: 144-154.
[9] Tang J, Wang Y, Han T, et al. Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial. BMC Gastroenterol, 2020, 20: 391.
[10] Jia J D, Xie W, Ding H G, et al. Utility and safety of tolvaptan in cirrhotic patients with hyponatremia: A prospective cohort study. Ann Hepatol, 2017, 16: 123-132.
[11] Yu YT, Liu J, Hu B, et al. Expert consensus on the use of human serum albumin in critically ill patients. Chin Med J (Engl), 2021, 134: 1639-1654.
[12] Lungren MP, Kim CY, Stewart JK, et al. Tunneled peritoneal drainage catheter placement for refractory ascites: single-center experience in 188 patients. J Vasc Interv Radiol, 2013, 24: 1303-1308.
[13] Kathpalia P, Bhatia A, Robertazzi S, et al. Indwelling peritoneal catheters in patients with cirrhosis and refractory ascites. Intern Med J, 2015, 45: 1026-1031.
[14] Corrigan M, Thomas R, Mcdonagh J, et al. Tunnelled peritoneal drainage catheter placement for the palliative management of refractory ascites in patients with liver cirrhosis. Frontline Gastroenterol, 2021, 12: 108-112.
[15] Stratmann K, Fitting D, Zeuzem S, et al. Establishing an indwelling peritoneal catheter as a standard procedure for hospitalized patients with ascites: Retrospective data on feasibility, effectiveness and safety. United European Gastroenterol J, 2019, 7: 673-681.
[16] Solbach P, Honer ZU Siederdissen C, Taubert R, et al. Home-based drainage of refractory ascites by a permanent-tunneled peritoneal catheter can safely replace large-volume paracentesis. Eur J Gastroenterol Hepatol, 2017, 29: 539-546.
[17] Macken L, Hashim A, Mason L, et al. Permanent indwelling peritoneal catheters for palliation of refractory ascites in end-stage liver disease: A systematic review. Liver Int, 2019, 39: 1594-1607.
[18] Macken L, Bremner S, Gage H, et al. Randomised clinical trial: palliative long-term abdominal drains vs large-volume paracentesis in refractory ascites due to cirrhosis. Aliment Pharmacol Ther, 2020, 52: 107-122.
[19] Bernardi M, Angeli P, Claria J, et al. Albumin in decompensated cirrhosis: new concepts and perspectives. Gut, 2020, 69: 1127-1138.
[20] Caraceni P, Riggio O, Angeli P, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER) an open-label randomised trial.pdf. Lancet, 2018,391:2417-2429.
[21] Di Pascoli M, Fasolato S, Piano S, et al. Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites. Liver Int, 2019, 39: 98-105.
[22] Caraceni P, Tufoni M, Zaccherini G, et al. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. J Hepatol, 2021, 74: 340-349.
[23] China L, Freemantle N, Forrest E, et al. A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis. N Engl J Med, 2021, 384: 808-817.
[24] Solà E, Solé C, Simón-Talero M, et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. J Hepatol, 2018, 69: 1250-1259.
[25] Sandi BB, Le?o GS, de Mattos AA, et al. Long-term albumin administration in patients with cirrhosis and ascites: a metaanalysis of randomized controlled trials. J Hepatol, 2021, 36:609-617.
[26] Sharma M, Singh S, Desai V, et al. Comparison of Therapies for Primary Prevention of Esophageal Variceal Bleeding: A Systematic Review and Network Meta-analysis. Hepatology, 2019, 69: 1657-1675.
[27] Serste T, Melot C, Francoz C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology, 2010, 52: 1017-1022.
[28] Krag A, Moller S, Burroughs AK, et al. Betablockers induce cardiac chronotropic incompetence. J Hepatol, 2012, 56: 298-299.
[29] Ferrarese A, Tikhonoff V, Casiglia E, et al. Hemodynamic Evaluation of Nonselective beta-Blockers in Patients with Cirrhosis and Refractory Ascites. Gastroenterol Res Pract, 2018, 2018: 4098210.
[30] Krag A, Wiest R, Albillos A, et al. The window hypothesis: haemodynamic and non-haemodynamic effects of beta-blockers improve survival of patients with cirrhosis during a window in the disease. Gut, 2012, 61: 967-969.
[31] Krag A, Wiest R, Albillos A, et al. The window hypothesis: haemodynamic and non-haemodynamic effects of beta-blockers improve survival of patients with cirrhosis during a window in the disease. Gut, 2012, 61: 967-969.
[32] Chirapongsathorn S, Valentin N, Alahdab F, et al. Nonselective beta-Blockers and Survival in Patients With Cirrhosis and Ascites: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol, 2016, 14: 1096-104,e9.
[33] Bossen L, Krag A, Vilstrup H, et al. Nonselective beta-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients. Hepatology, 2016, 63: 1968-1976.
[34] Kang SH, Lee M, Kim MY, et al. The longitudinal outcomes of applying non-selective beta-blockers in portal hypertension: real-world multicenter study. Hepatol Int, 2021, 15: 424-436.
[35] De Franchis R, Baveno VIF. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol, 2015, 63: 743-752.
[36] Thiele M, Albillos A, Abazi R, et al. Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials. Liver Int, 2015, 35: 2009-2016.
[37] Yoon KT, Liu H, Lee SS. beta-blockers in advanced cirrhosis: More friend than enemy. Clin Mol Hepatol, 2021, 27: 425-436.
[38] Boyer TD, Sanyal AJ, Wong F, et al. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1. Gastroenterology, 2016, 150: 1579-1589 e2.
[39] Wong F, Pappas SC, Curry MP, et al. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. N Engl J Med, 2021, 384: 818-828.
[40] Thomson MJ, Taylor A, Sharma P, et al. Limited Progress in Hepatorenal Syndrome (HRS) Reversal and Survival 2002-2018: A Systematic Review and Meta-Analysis. Dig Dis Sci, 2020, 65: 1539-1548.
[41] Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology, 2015, 62: 567-574.
[42] Mohamed MMG, Rauf A, Adam A, et al. Terlipressin effect on hepatorenal syndrome: Updated meta-analysis of randomized controlled trials. JGH Open, 2021, 5: 896-901.
[43] Sharma P, Moore K, Ganger D, et al. Role of Terlipressin and Albumin for Hepatorenal Syndrome in Liver Transplantation. Liver Transpl, 2020, 26: 1328-1336. |
